In a recent study published in Cancer Immunology Research, researchers at the Icahn School of Medicine at Mount Sinai have made significant progress in cancer vaccine development. The team has created a method to produce billions of rare immune cells known as conventional type I dendritic cells (cDC1s). These cells are crucial for triggering immune responses against tumors but are typically scarce and difficult to isolate.
The breakthrough involves a serum-free culture system that can generate nearly 3 billion functional cDC1s from just 1 million hematopoietic stem cells derived from cord blood. This achievement marks an important step towards creating universal cell-based cancer vaccines.
“This is a major step toward the creation of universal cell-based cancer vaccines,” said Dr. Nina Bhardwaj, Ward-Coleman Chair in Cancer Research and Director of the Vaccine and Cell Therapy Laboratory at Mount Sinai. “Conventional type I dendritic cells are essential for mobilizing the immune system to fight cancer, but they’re almost impossible to obtain at scale. We’ve now overcome that barrier.”
Dr. Sreekumar Balan, Assistant Professor of Medicine at Mount Sinai, highlighted the potential applications: “Our method not only expands cDC1s in large numbers but also retains their ability to stimulate strong anti-tumor immunity in preclinical models.”
The research involved collaboration with the Mater Research Institute in Brisbane, Australia, using humanized mouse models to validate lab-grown cDC1s as a potential cancer vaccine.
“This is not just about scaling up a cell type,” added Dr. Bhardwaj. “It’s about transforming how we design immune therapies, making them more effective, accessible, and personalized.”
Funding for this study was provided by the Waldman Melanoma Research Fund and the Antidote Health Foundation For Cure of Cancer.
###
